Information for Readers
2017-02-23
Information for Readers
Hepatobiliary & Pancreatic Diseases International
Copyright 2017, Hepatobiliary & Pancreatic Diseases International. All rights reserved.
www.hbpdint.com
Aims and Scope
Hepatobiliary & Pancreatic Diseases Internationalpublishes peer-reviewed original papers, reviews (meta-analysis, systematic review) and editorials concerned with clinical practice and research in the felds of hepatobiliary and pancreatic diseases. Papers cover the medical, surgical, radiological, pathological, biochemical, physiological and histological aspects of the subject areas under the headings Liver, Biliary, Pancreas, Transplantation, Research, Special Reports, Editorials, Review Articles, Brief Reports, Clinical Summary, New Techniques, Clinical Images and Case Reports. The journal also deals with the basic sciences and experimental work. All submitted papers are reviewed by at least two referees expert in the feld of the submitted paper. For detailed instructions concerning the submission of manuscripts, please refer to the Instructions for Authors in each issue of the journal.
Editorial Offce
Hepatobiliary & Pancreatic Diseases International, the First Affliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China. Tel: +86-571-87236559, +86-571-87236600; Fax: +86-571-87236559; Email: hbpdint@126.com, hbpdje@zju.edu.cn.
Business Correspondence and Advertising Principles
All matters relating to orders, subscriptions, back issues, offprints, advertisement booking and general enquiries should be addressed to: Yan-Ping Dong; Email: hbpdint@126. com; visit our website athttp://www.hbpdint.com.Advertisements in this journal have to be reviewed to comply with the principles governing advertising in this journal. The appearance of advertising inHepatobiliary & Pancreatic Diseases Internationalis not a guarantee or endorsement of the product or the claims made for the product.
Subscription Rates
The journal is published 6 times per year and the prices for 2017 are as follows: Institution: US$400 (rest of world); Personal: US$200. The journal is despatched to subscribers outside China by surface air-lifted delivery.
Database
Hepatobiliary & Pancreatic Diseases Internationalis abstracted and indexed in Chemical Abstracts (CA), EMBASE/Excerpta Medica (EM), Index Medicus (IM)/MEDLINE, Science Citation Index Expanded (SCI-E), SCOPUS. Electronic availabilityhttp://www.hbpdint.com.The impact factor of the journal is 1.724 (ISI 2015Journal Citation Reports).
Disclaimer
The publisher, the hospital and the editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily refect those of the publisher, the hospital or the editors, neither does the publication of advertisements constitute any endorsement by the publisher, the hospital or the editors of the products advertised.
Copyright and Photocopying
©2017Hepatobiliary & Pancreatic Diseases International, the First Affliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. All rights reserved. No part of this publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the owner of the journal.
○8The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).
10.1016/S1499-3872(16)60177-7)
杂志排行
Hepatobiliary & Pancreatic Diseases International的其它文章
- Meetings and Courses
- Editors
- Limitations of current liver transplant immunosuppressive regimens: renal considerations
- Roles of microRNAs in immunopathogenesis of non-alcoholic fatty liver disease revealed by integrated analysis of microRNA and mRNA expression profles
- Quercetin protects liver injury induced by bile duct ligation via attenuation of Rac1 and NADPH oxidase1 expression in rats
- Silibinin induces hepatic stellate cell cycle arrest via enhancing p53/p27 and inhibiting Akt downstream signaling protein expression